A detailed history of Bank Of Nova Scotia transactions in Alkermes Plc. stock. As of the latest transaction made, Bank Of Nova Scotia holds 17,405 shares of ALKS stock, worth $479,159. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,405
Previous 12,857 35.37%
Holding current value
$479,159
Previous $348,000 20.4%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$23.21 - $27.24 $105,559 - $123,887
4,548 Added 35.37%
17,405 $419,000
Q1 2024

May 14, 2024

SELL
$26.4 - $32.56 $92,268 - $113,797
-3,495 Reduced 21.37%
12,857 $348,000
Q4 2023

Feb 12, 2024

BUY
$23.37 - $28.68 $4,884 - $5,994
209 Added 1.29%
16,352 $453,000
Q3 2023

Nov 14, 2023

BUY
$27.17 - $31.97 $66,946 - $78,774
2,464 Added 18.01%
16,143 $452,000
Q2 2023

Aug 03, 2023

SELL
$28.34 - $33.63 $4,647 - $5,515
-164 Reduced 1.18%
13,679 $428,000
Q1 2023

May 11, 2023

BUY
$25.31 - $29.02 $8,402 - $9,634
332 Added 2.46%
13,843 $390,000
Q4 2022

Feb 09, 2023

SELL
$21.94 - $26.24 $419,778 - $502,049
-19,133 Reduced 58.61%
13,511 $353,000
Q3 2022

Nov 10, 2022

BUY
$22.0 - $31.87 $184,668 - $267,516
8,394 Added 34.61%
32,644 $729,000
Q2 2022

Aug 08, 2022

BUY
$26.4 - $30.54 $640,200 - $740,595
24,250 New
24,250 $722,000
Q2 2022

Aug 05, 2022

SELL
$26.4 - $30.54 $740,995 - $857,196
-28,068 Closed
0 $0
Q1 2022

May 09, 2022

SELL
$23.07 - $27.99 $291,512 - $353,681
-12,636 Reduced 31.04%
28,068 $738,000
Q4 2021

Feb 11, 2022

BUY
$21.47 - $32.08 $537,029 - $802,417
25,013 Added 159.41%
40,704 $947,000
Q3 2021

Nov 12, 2021

BUY
$23.37 - $32.13 $366,698 - $504,151
15,691 New
15,691 $484,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.52B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Bank Of Nova Scotia Portfolio

Follow Bank Of Nova Scotia and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Nova Scotia with notifications on news.